Skip to main content
. 2015 Mar;11(1):26–38. doi: 10.1183/20734735.015414

Figure 4.

Figure 4

The COMPACT study demonstrated the difference in outcomes associated with management of only lower airways inflammation (budesonide) compared with systemic (upper and lower airways) inflammation management (montelukast) in asthmatic patients without (a) and with (b) rhinitis. Reproduced from [31, 32] with permission from the publishers.